한글목차

세계 광견병 백신 시장의 미래는 병원, 재택치료, 전문 클리닉 시장에서의 기회로 인해 유망합니다. 세계 광견병 백신 시장은 2025-2031년 4.4%의 연평균 복합 성장률(CAGR)로 2031년까지 약 13억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 광견병 위험에 대한 인식 증가와 여우, 너구리 등 야생 동물의 광견병 예방에 대한 노력의 확대입니다.

• 제품 유형별로는 실현 가능성, 안전성, 높은 면역원성 등 많은 장점이 있고, 노출 전 및 노출 후 예방에 사용되므로 예측 기간 중 가장 높은 성장이 예상되는 것은 베로셀이라고 Lucintel은 예측했습니다.
• 최종 용도별로는 병원에서 광견병 예방접종 처방이 증가함에 따라 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로 보면 북미는 탄탄한 의료 인프라와 제약사 증가로 인해 가장 규모가 큰 지역이 될 것입니다.

광견병 백신 시장에서의 전략적 성장 기회

광견병 백신 시장은 주요 용도에서 몇 가지 전략적 성장 기회를 제공합니다. 여기에는 백신의 기술 발전, 인지도 향상, 공중 보건 구상 증가 등이 포함됩니다.

• 인간 백신 접종 프로그램: 특히 고위험 지역에서 인간 광견병 백신 접종 프로그램 개발은 큰 성장 기회가 될 수 있습니다. 서비스 접근성 향상과 집중적인 캠페인은 질병 통제와 예방을 촉진할 수 있습니다.
• 동물 백신 접종에 대한 노력: 광견병의 확산을 막기 위해 동물에 대한 백신 접종의 필요성이 높아지고 있습니다. 동물 백신 접종에 힘쓰면 광견병 발생을 억제하고 사람에 대한 감염을 줄일 수 있습니다.
• 혼합백신 개발: 여러 질병을 예방할 수 있는 혼합백신을 제공하는 것도 성장 기회 중 하나입니다. 이러한 백신의 접종 일정이 보다 간단해져 환자들의 접종 순응도가 높아질 수 있습니다.
• 혁신적인 전달 방법: 또 다른 가능성은 마이크로니들 패치나 경구용 백신과 같은 혁신적인 백신 전달 방법을 연구하는 것입니다. 이는 백신의 수용률을 높이고 복용을 보다 편리하게 하는 데 도움이 될 수 있습니다.
• 시장 접근성 확대: 유통 및 물류 개선은 신흥 시장에서의 접근성을 향상시켜 시장 확대의 기회를 제공합니다. 이러한 노력은 그동안 부족했던 백신의 접근성을 개선하고, 백신에 대한 접근성이 낮은 지역에도 백신이 널리 보급될 수 있도록 하여 시장 침투를 촉진할 수 있습니다.

이러한 성장 기회는 기술 혁신을 촉진하고, 접근성을 확대하며, 질병 대책을 개선함으로써 광견병 백신 시장을 형성하고 있습니다. 전 세계 광견병 문제를 효과적으로 해결하고 공중보건에 대한 개입을 강화하기 위해서는 이러한 과제를 해결해야 합니다.

광견병 백신 시장 성장 촉진요인 및 과제

광견병 백신 시장은 기술 발전, 경제적 요인, 규제적 고려사항 등 다양한 시장 성장 촉진요인 및 과제에 영향을 받고 있습니다. 이러한 요소들을 이해하는 것은 시장 개발에 있으며, 매우 중요합니다.

광견병 백신 시장을 촉진하는 요인은 다음과 같습니다. :

• 기술 발전: 백신 기술 시장 성장은 혁신적인 재조합 백신과 혼합 백신에 기인합니다. 이러한 변화는 제품의 안전성과 효능을 향상시키고 질병을 더 잘 통제할 수 있도록 도와줍니다.
• 인식 및 교육 향상: 광견병과 예방접종에 대한 인식이 높아짐에 따라 백신에 대한 수요가 증가하고 있습니다. 따라서 백신 접종률을 높이기 위해서는 건강 캠페인과 교육 활동이 필요합니다.
• 정부의 구상: 광견병 예방접종 프로그램에 대한 정부의 지원 정책 및 자금 지원으로 시장 확대가 촉진되었습니다. 예방접종률을 높이고 발병을 억제하는 데 있으며, 정부의 역할은 아무리 강조해도 지나치지 않습니다.
• 백신에 대한 접근성 확대: 유통 시스템과 물류 개선으로 인해, 백신 접근성이 낮은 지역에서도 이전보다 더 많은 백신을 접종할 수 있게 되었습니다. 개선된 콜드체인 관리와 함께 대상별 프로그램들이 백신의 광범위한 접근을 용이하게 하고 있습니다.
• 연구개발: 새로운 전달 시스템 등 백신 기술의 혁신이 계속되고 있습니다. 이러한 연구개발 없이는 보다 효과적이고 편리한 백신 접종 방법을 개발할 수 없습니다.

광견병 백신 시장이 해결해야 할 과제는 다음과 같습니다. :

• 규제적 장애물: 제품 개발 중 또는 백신 승인을 받으려 할 때, 다양한 국제 기준을 준수하는 것은 복잡한 규제 요건으로 인해 어려울 수 있습니다. 국제적으로 충족해야 하는 기준이 여러 개이기 때문에 백신의 승인 절차를 진행하는 것이 어렵고, 제품 개발 및 시장 개발을 복잡하게 만들고 있습니다.
• 높은 비용: 첨단 백신의 개발 및 제조 비용은 매우 높으며, 특히 아프리카처럼 광견병이 널리 퍼져 있는 저자원 국가에서는 가격 책정 및 구매 용이성에 영향을 미칠 수 있습니다. 이런 유형의 백신의 제조에는 많은 자금이 필요하며, 높은 비용이 소요됩니다.
• 백신 접종에 대한 거부감: 백신 접종률 향상은 백신 접종에 대한 거부감과 잘못된 정보에 대한 대처에 달려있습니다. 백신 접종에 대한 장벽을 없애기 위해서는 일반 대중에 대한 교육과 참여가 필요합니다.

이러한 시장 성장 촉진요인 및 과제는 기술 혁신, 접근성, 공중 보건 노력에 영향을 미치며, 광견병 백신 시장에 큰 영향을 미칩니다. 이러한 요소들을 해결하면 광견병 대책을 개선하고 백신 접종률을 확대할 수 있습니다.

목차

제1장 개요

제2장 세계의 광견병 백신 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 광견병 백신 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 광견병 백신 시장 : 제품 유형별
  • BHK(Baby Hamster Kidney)
  • 광견병용 PCEC(Purified Chick Embryo Cell) 백신
  • 광견병용 베로 세포 백신
  • 기타
• 세계의 광견병 백신 시장 : 백신 접종 유형별
  • 폭로전 백신 접종(PEV)
  • 폭로 후 예방(PEP)
• 세계의 광견병 백신 시장 : 용도별
  • 동물
  • 인간
• 세계의 광견병 백신 시장 : 최종 용도별
  • 병원
  • 재택 의료
  • 전문 클리닉
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 광견병 백신 시장 : 지역별
• 북미의 광견병 백신 시장
• 유럽의 광견병 백신 시장
• 아시아태평양의 광견병 백신 시장
• 기타 지역의 광견병 백신 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 광견병 백신 시장의 성장 기회 : 제품의 유형별
  • 세계의 광견병 백신 시장의 성장 기회 : 백신 접종 유형별
  • 세계의 광견병 백신 시장의 성장 기회 : 용도별
  • 세계의 광견병 백신 시장의 성장 기회 : 최종 용도별
  • 세계의 광견병 백신 시장의 성장 기회 : 지역별
• 세계의 광견병 백신 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 광견병 백신 시장의 생산능력 확대
  • 세계의 광견병 백신 시장에서의 기업인수합병(M&A), 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 개요

• Serum Institute of India
• Novartis
• Cadila Pharmaceuticals
• Merck
• Sanofi
• ADS Diagnostic
• GSK

영문목차

The future of the global rabies vaccine market looks promising with opportunities in the hospital, home care, and specialty clinic markets. The global rabies vaccine market is expected to reach an estimated $1.3 billion by 2031 with a CAGR of 4.4% from 2025 to 2031. The major drivers for this market are the rising awareness of the risks of rabies and growing efforts to control rabies in wildlife populations, such as foxes and raccoons.

• Lucintel forecasts that, within the product type category, vero cell is expected to witness the highest growth over the forecast period due to its numerous benefits, such as its feasibility, safety, and high immunogenicity, and its use for pre-and post-exposure prophylaxis.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period due to the increasing number of rabies vaccination prescriptions issued within these facilities.
• In terms of regions, North America will remain the largest region due to its robust healthcare infrastructure and the growing number of pharmaceutical companies in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Rabies Vaccine Market

Numerous technological advancements, changing healthcare needs, and an increasing global focus on disease prevention are driving the current trends in the rabies vaccine market.

• Enhanced Vaccine Technologies: These include recombinant and DNA vaccines that have improved their effectiveness and safety profiles for rabies vaccination. They offer more efficacious and less mild alternatives to the existing rabies vaccines.
• Combination Vaccines: More people today prefer combination vaccines that protect against multiple diseases, including rabies. This simplifies vaccination schedules and promotes compliance among patients.
• Expanded Access and Distribution: Currently, there is a growing focus on expanding access to low-cost rabies vaccines in low-resource settings. Better distribution networks and public health awareness campaigns are leading to higher immunization coverage rates, thus helping to control these diseases.
• Increased Focus on Animal Vaccination: In high rabies incidence areas, animal vaccination is now more important than ever before. Failure to vaccinate animals implies that humans can be affected as a consequence of an outbreak of this disease.
• Novel Delivery Methods: Ongoing studies are exploring novel methods of administering vaccines, such as microneedle patches and oral vaccines, to make vaccination more effective, especially for humans and animals.

These trends improve vaccine technology and expand access while enhancing other disease prevention strategies, thereby reshaping the rabies vaccine market, which contributes significantly to better overall worldwide control measures against rabies.

Recent Developments in the Rabies Vaccine Market

The rabies vaccine market is experiencing considerable progress as a result of technological innovation, regulatory amendments, and increased concern for disease prevention. These developments are shaping the future of rabies vaccination.

• Recombinant Vaccines: The introduction of recombinant rabies vaccines has made them safer and more effective. They involve genetic engineering, leading to newer, better immunizations with fewer side effects.
• Expanded Vaccination Campaigns: Global efforts to expand rabies vaccination campaigns are leading to greater coverage in high-risk areas. These interventions encompass human and animal vaccination schemes designed to contain outbreaks.
• Combination Vaccines: The development of combination vaccines that prevent multiple diseases is gaining momentum. Such vaccines make it easier to immunize many people at once and thus contribute positively to public health outcomes.
• Improved Distribution Networks: Advances in distribution and logistics have improved accessibility to rabies vaccines in remote and underserved areas. This includes better cold chain management and targeted vaccination programs.
• Innovative Research: Continued research on alternative vaccine technologies, such as oral vaccines and microneedle vaccinations, is advancing the field. These innovations aim to enhance vaccine delivery methods and improve patient compliance, among other goals.

By enhancing vaccine safety, increasing availability, and driving innovation, these developments significantly impact the rabies vaccine market. They are important in improving worldwide efforts to control this disease by preventing its spread through various channels.

Strategic Growth Opportunities for Rabies Vaccine Market

The rabies vaccine market offers several strategic growth opportunities in major applications. These include technological advancements in vaccines, improved awareness, and increased public health initiatives.

• Human Vaccination Programs: Developing human rabies vaccination programs, particularly in high-risk regions, represents a huge opportunity for growth. The control and prevention of disease can be facilitated through better access to services and focused campaigns.
• Animal Vaccination Initiatives: There is an increasing need to vaccinate animals to prevent the spread of rabies. Concentrating more on animal vaccinations will help control outbreaks and decrease human cases.
• Combination Vaccine Development: Offering combination vaccines that can prevent multiple illnesses is another area of opportunity for growth. Immunization schedules for these vaccines will be easier, making it easier for patients to comply with them.
• Innovative Delivery Methods: Another possibility is research into innovative vaccine delivery methods, such as microneedle patches and oral vaccines, which have growth potential. They can help enhance vaccine acceptance rates and make the doses more convenient.
• Expanded Market Access: Improvement in distribution and logistics, leading to better accessibility in emerging markets, presents expansion opportunities. Such efforts would result in wider availability of previously scarce vaccines across underserved sectors, thereby driving further market penetration.

These growth opportunities are shaping the rabies vaccine market by fostering innovation while also expanding access and improving disease control measures. They must be addressed if global rabies issues are to be dealt with effectively, thus enhancing public health interventions.

Rabies Vaccine Market Driver and Challenges

The rabies vaccine market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory considerations. Understanding these elements is crucial for market development.

The factors responsible for driving the rabies vaccine market include:

• Technological Advancements: Market growth in vaccine technology can be attributed to innovative recombinant and combination vaccines. These changes have made it possible to control diseases better by increasing product safety and effectiveness.
• Increased Awareness and Education: Demand for vaccines is increasing due to improved awareness about rabies and its prevention through vaccination. Therefore, health campaigns and educational efforts are necessary for enhancing vaccination rates.
• Government Initiatives: Market expansion has been fueled by supportive government policies and funding for rabies vaccination programs. The role played by governments in scaling up immunization coverage and controlling outbreaks cannot be overemphasized.
• Expanded Access to Vaccines: Better distribution systems and logistics are making underserved areas more accessible, enabling them to receive more vaccines than before. Improved cold chain management, coupled with targeted programs, facilitates wider availability of vaccines.
• Research and Development: There is ongoing innovation in vaccine technologies, such as new delivery systems. Without this research, there would be no opportunity to develop more effective or convenient ways of vaccinating people.

Challenges in the rabies vaccine market include:

• Regulatory Hurdles: Complying with different international standards during product development or when trying to obtain approval for a vaccine can be difficult due to complex regulatory requirements. This makes navigating procedures for vaccine approval challenging and complicates product development and market entry due to the multiple standards that must be met internationally.
• High Costs: The developing and manufacturing costs associated with advanced vaccines can be very high, impacting pricing and affordability, particularly among low-resource countries where rabies is highly prevalent, such as in Africa. Producing these types of vaccines requires a significant amount of funding, creating high costs.
• Vaccine Hesitancy: Increasing vaccination rates hinges on addressing vaccine hesitancy and misinformation. Public education and engagement are required to remove barriers to vaccine acceptance.

These drivers and challenges significantly impact the rabies vaccine market by influencing innovation, access, and public health efforts. Rabies control can be improved, and vaccination coverage extended by addressing these elements.

List of Rabies Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies rabies vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the rabies vaccine companies profiled in this report include-

• Serum Institute of India
• Novartis
• Cadila Pharmaceuticals
• Merck
• Sanofi
• ADS Diagnostic
• GSK

Rabies Vaccine by Segment

The study includes a forecast for the global rabies vaccine market by product type, vaccination type, application, end use, and region.

Rabies Vaccine Market by Product Type [Analysis by Value from 2019 to 2031]:

• Baby Hamster Kidney
• Purified Chick Embryo Cell Rabies Vaccine
• Vero Cell Rabies Vaccine
• Others

Rabies Vaccine Market by Vaccination Type [Analysis by Value from 2019 to 2031]:

• Pre-Exposure Vaccination (PEV)
• Post-Exposure Prophylaxis (PEP)

Rabies Vaccine Market by Application [Analysis by Value from 2019 to 2031]:

• Animal
• Human

Rabies Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Rabies Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Rabies Vaccine Market

The rabies vaccine market is changing rapidly due to progress in vaccine technology, increased awareness, and differing global health priorities. These trends are evident in recent developments in the United States, China, Germany, India, and Japan, which demonstrate global efforts to curb and prevent rabies.

• USA: New safety-enhanced rabies vaccines with improved post-exposure prophylaxis regimens have been developed. Recent research has led to recombinant vaccines that are more effective and have fewer side effects.
• China: Rabies vaccination programs are being expanded in China, especially in rural areas where the disease is rampant. The government has also increased funding for vaccination campaigns and studies on more potent vaccines.
• Germany: Germany's focus has shifted toward combination vaccines offering protection against many diseases, including rabies. This approach aims to create a consolidated immunization program that will increase the number of immunized individuals.
• India: New intervention programs revolve around the wider distribution of anti-rabies vaccines among vulnerable communities. Access to vaccines will be improved by conducting campaigns in public health systems and partnering with organizations involved in immunization.
• Japan: In Japan, investments in advanced research on rabies vaccinations, including novel delivery mechanisms, have been made. These innovations aim to improve the efficacy of vaccines, particularly for travelers and pet owners who prioritize convenience.

Features of the Global Rabies Vaccine Market

Market Size Estimates: Rabies vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Rabies vaccine market size by various segments, such as by product type, vaccination type, application, end use, and region in terms of ($B).

Regional Analysis: Rabies vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, vaccination types, applications, end uses, and regions for the rabies vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the rabies vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the rabies vaccine market by product type (baby hamster kidney, purified chick embryo cell rabies vaccine, vero cell rabies vaccine, and others), vaccination type (pre-exposure vaccination (PEV) and post-exposure prophylaxis (PEP)), application (animal and human), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Rabies Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Rabies Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Rabies Vaccine Market by Product Type
  • 3.3.1: Baby Hamster Kidney
  • 3.3.2: Purified Chick Embryo Cell Rabies Vaccine
  • 3.3.3: Vero Cell Rabies Vaccine
  • 3.3.4: Others
• 3.4: Global Rabies Vaccine Market by Vaccination Type
  • 3.4.1: Pre-Exposure Vaccination (PEV)
  • 3.4.2: Post-Exposure Prophylaxis (PEP)
• 3.5: Global Rabies Vaccine Market by Application
  • 3.5.1: Animal
  • 3.5.2: Human
• 3.6: Global Rabies Vaccine Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Homecare
  • 3.6.3: Specialty Clinics
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Rabies Vaccine Market by Region
• 4.2: North American Rabies Vaccine Market
  • 4.2.1: North American Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.2.2: North American Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.3: European Rabies Vaccine Market
  • 4.3.1: European Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.3.2: European Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.4: APAC Rabies Vaccine Market
  • 4.4.1: APAC Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.4.2: APAC Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.5: ROW Rabies Vaccine Market
  • 4.5.1: ROW Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.5.2: ROW Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Rabies Vaccine Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Rabies Vaccine Market by Vaccination Type
  • 6.1.3: Growth Opportunities for the Global Rabies Vaccine Market by Application
  • 6.1.4: Growth Opportunities for the Global Rabies Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Rabies Vaccine Market by Region
• 6.2: Emerging Trends in the Global Rabies Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Rabies Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Rabies Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Serum Institute of India
• 7.2: Novartis
• 7.3: Cadila Pharmaceuticals
• 7.4: Merck
• 7.5: Sanofi
• 7.6: ADS Diagnostic
• 7.7: GSK